GET DAILY SIGNALSHaemonetics (HAE) Delivers Fiscal Q2 Beat on Plasma Momentum
Key Takeaways
- Haemonetics reported fiscal second-quarter 2027 revenue of $357.8 million, up 9.3% year over year and ahead of the roughly $346.8 million consensus estimate.
- Adjusted earnings per share (EPS) rose 6% to $1.35, topping the $1.30 analyst consensus, while GAAP (Generally Accepted Accounting Principles) EPS climbed 23% to $1.00.
- Plasma revenue surged 16.5% to $162.6 million, driven by the expanding CSL relationship and broader adoption of the Persona Plus suite.
- Management raised full-year fiscal 2027 revenue guidance for the second straight quarter but lowered its operating-margin expansion target to reflect ramp-up investments.
- Free cash flow reached $104 million in the quarter, up 17%, as strong cash generation continued to strengthen the balance sheet.
Why This Quarter Matters
Haemonetics Corporation (NYSE: HAE) is a global healthcare company focused on blood and plasma collection, blood management, and hospital technologies. Its fiscal 2027 second quarter, which ended September 26, 2026, carries particular weight because it reflects the early economics of the company's expanded relationship with plasma leader CSL. Heading into the report, investors were watching whether accelerating plasma volumes could lift both revenue and profitability, especially after a strong stock run-up of roughly 48% since the prior earnings report. The results matter beyond a single quarter: they help validate whether HAE can convert a major customer win into durable, multi-year growth while managing the cost of scaling up production and distribution capacity. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
HAE delivered a beat-and-raise quarter led by its plasma business. Net revenue increased 9.3% to $357.8 million, exceeding the consensus estimate of about $346.8 million. Adjusted EPS grew 6% to $1.35, ahead of the $1.30 consensus, while GAAP EPS rose 23.5% to $1.00. Organic revenue growth accelerated to 10% in the quarter, up from 6% in the first quarter.
By segment, Apheresis revenue rose 12.6% to $204.8 million, with plasma revenue up 16.5% to $162.6 million. MedSurg revenue increased 5.1% to $153 million. Adjusted gross margin expanded roughly 140 basis points (bps) to 61.9%, though that figure included an approximately 200 bps benefit from a tariff refund; excluding that one-time item, gross margin was essentially flat. Adjusted operating margin came in at 26.3%, down 40 bps year over year, as operating expenses rose 15% on investments tied to growth initiatives, higher performance-based compensation, and increased freight costs.
Market Reaction and Investor Sentiment
HAE entered the report near a 52-week high, with shares around $127 after a significant post-earnings rally earlier in the fiscal year, which raised the bar for a positive reaction. The company's second consecutive beat-and-raise quarter supported the growth narrative, but the market's focus has shifted toward profitability quality. A margin guide-down, driven partly by a non-recurring tariff refund benefit and rising costs tied to the CSL ramp, tempered the headline strength. Investors are weighing the faster-than-expected revenue acceleration against the reality that earnings are not yet growing at the same pace, creating a more balanced sentiment heading into the remainder of fiscal 2027.
Forward Outlook and Key Factors to Monitor
HAE raised its full-year fiscal 2027 outlook, now expecting reported revenue growth of 8% to 11% and organic revenue growth of 6% to 9%, both up from prior guidance. However, the company lowered its adjusted operating-margin expansion target to 0 to 50 bps from 50 to 100 bps, reflecting investments made ahead of expected plasma share gains.
Looking ahead, investors should monitor the timing and economics of the CSL rollout, where Nexus PCS devices with the full Persona Plus suite are expected to reach all of CSL's U.S. plasma centers by the end of calendar 2027. Management has indicated the relationship could add roughly 40% to 50% to plasma volumes over time. Because contract economics are weighted toward the fourth quarter, second-half growth and margin performance depend heavily on successful execution of these conversions.
Additional factors to watch include gross margin trends as ramp-up production costs are capitalized into inventory, ongoing cost pressures from freight, fuel, and performance-based compensation, and progress in MedSurg, where growth moderated as the TEG 5000 capital cycle winds down. Free cash flow conversion, now guided above 80% of adjusted net income, will also be a key indicator of how efficiently the company funds its growth. From what I see, this is important because execution on the CSL ramp will determine whether the growth story holds.
AI Screener in My Research Process
I often turn to Tickeron’s AI Screener when preparing for earnings reports like this one. The tool lets me quickly filter stocks by fundamentals, technical patterns, and performance metrics to put results in broader context. It has become a practical part of how I cross-check ideas and identify comparable names without spending hours on manual screens. In this case, it helped confirm where HAE stands relative to peers in the healthcare equipment space.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for HAE shows an upward move is likely
HAE's Aroon Indicator triggered a bullish signal on November 06, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 211 similar instances where the Aroon Indicator showed a similar pattern. In 161 of the 211 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 76%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on HAE as a result. In 43 of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where HAE advanced for three days, in 233 of 337 cases, the price rose further within the following month. The odds of a continued upward trend are 69%.
Bearish Trend Analysis
The 10-day RSI Indicator for HAE moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 30 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 59 cases where HAE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 69%.
The Moving Average Convergence Divergence Histogram (MACD) for HAE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 29 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HAE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
HAE broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. HAE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 40 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 66 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.518) is normal, around the industry mean (4.137). P/E Ratio (57.659) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (1.676) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.668) is also within normal values, averaging (40.124).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of blood processing systems
Industry MedicalNursingServices
Advertisement